The use of renal mass biopsy to guide treatment decisions for small renal tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.
The use of renal mass biopsy to guide treatment decisions for small renal tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.
Most small renal masses are detected incidentally in imaging and their current treatment is direct surgery, said lead researcher Dr. Pari Pandharipande, a radiologist in the abdominal imaging and interventional radiology department at MGH. Many small renal masses, however, are benign-or indolent if they are malignant-and so less invasive management strategies should be considered, she said during a presentation at the RSNA meeting.
After constructing a decision-analytic Markov model, the researchers determined surgery was about $3500 more expensive than biopsy and resulted in a comparable minimally lower life expectancy. Biopsy therefore dominated surgery from a cost-effectiveness perspective.
The researchers assumed a biopsy sensitivity of 90% and specificity of 100%. The researchers also assumed a postsurgery mortality rate of 1.6%. Among imaging-detected masses, 77% were assumed to reflect renal cell carcinoma.
Biopsy did not dominate surgery under some conditions, for example, when sensitivity was lower than 78%, when surgical mortality was less than 1%, and when prevalence of renal cancer was greater than 87%.
The researchers used a competing-choices cost-effectiveness analysis to compare biopsy with surgery. If one strategy had a lower life expectancy and a higher cost than another, it was considered dominated. If not, an incremental cost-effectiveness ratio was computed and strategy preference was assessed based on an assumed $75,000 per quality adjusted life year societal willingness-to-pay threshold. The long-term outcomes of life expectancy and lifetime costs after biopsy and surgery were estimated by using a decision-analytic Markov model. The cohort in the base-case analysis was 65-year-old men with incidental renal masses.
All patients started with small incidental renal masses and underwent either surgery or biopsy. Patients receiving biopsy could have a true or false positive or negative result. Patients with negative biopsy results underwent CT surveillance for up to five years. Patients with positive and nondiagnostic biopsy specimens underwent direct surgery.
This story has been updated to better reflect Dr. Pandharipande's research.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.